Neoadjuvant phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patients treated with temozolomide

Michael Brada, S. Ashley, A. Dowe, A. Gonsalves, A. Huchet, G. Pesce, M. Reni, F. Saran, B. Wharram, M. Wilkins, P. Wilkins

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background: The aim of this study was to assess the efficacy of new agents in patients with malignant glioma in a neoadjuvant setting not confounded by surgery. The first study of neoadjuvant temozolomide aimed to provide a benchmark for future evaluation of new treatments. Patients and methods: This was a multicentre phase II study of chemotherapy in patients with histologically verified glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA) who had undergone biopsy alone. Patients were planned to receive two cycles of temozolomide at 200 mg/m2 orally daily for 5 days at a 28-day interval prior to radiotherapy. Response was assessed by two central observers on pre- and post-chemotherapy enhanced scans using bi-dimensional criteria and as progression-free survival (PFS) at the time of second assessment prior to radiotherapy. Withdrawal from the study due to worsening clinical condition was, in the absence of second imaging, assessed as progressive disease. Survival and quality of life (QOL) were secondary endpoints. Results: Between August 1999 and June 2002, 188 patients from 15 UK and two Italian centres were entered into the study and 187 were analysed. Overall, 162 patients were assessable for response; seven had partial and 25 had minimal response. The objective response rate was 20% [95% confidence interval (CI) 14-26%] and PFS prior to commencing radiotherapy was 64% (95% CI 57-72%). The median survival was 10 months, and 1-year survival 41%. The median survival of responders was 16 months compared to 3 months in patients with progressive disease (P

Original languageEnglish
Pages (from-to)942-949
Number of pages8
JournalAnnals of Oncology
Volume16
Issue number6
DOIs
Publication statusPublished - Jun 2005

Fingerprint

temozolomide
Proxy
Glioma
Multicenter Studies
Radiotherapy
Survival
Drug Therapy
Disease-Free Survival
Confidence Intervals
Benchmarking
Astrocytoma
Glioblastoma
Quality of Life

Keywords

  • Malignant glioma
  • New agents
  • Temozolomide

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Neoadjuvant phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patients treated with temozolomide. / Brada, Michael; Ashley, S.; Dowe, A.; Gonsalves, A.; Huchet, A.; Pesce, G.; Reni, M.; Saran, F.; Wharram, B.; Wilkins, M.; Wilkins, P.

In: Annals of Oncology, Vol. 16, No. 6, 06.2005, p. 942-949.

Research output: Contribution to journalArticle

Brada, Michael ; Ashley, S. ; Dowe, A. ; Gonsalves, A. ; Huchet, A. ; Pesce, G. ; Reni, M. ; Saran, F. ; Wharram, B. ; Wilkins, M. ; Wilkins, P. / Neoadjuvant phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patients treated with temozolomide. In: Annals of Oncology. 2005 ; Vol. 16, No. 6. pp. 942-949.
@article{127ee5ffc0694efa97de5daed208483c,
title = "Neoadjuvant phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patients treated with temozolomide",
abstract = "Background: The aim of this study was to assess the efficacy of new agents in patients with malignant glioma in a neoadjuvant setting not confounded by surgery. The first study of neoadjuvant temozolomide aimed to provide a benchmark for future evaluation of new treatments. Patients and methods: This was a multicentre phase II study of chemotherapy in patients with histologically verified glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA) who had undergone biopsy alone. Patients were planned to receive two cycles of temozolomide at 200 mg/m2 orally daily for 5 days at a 28-day interval prior to radiotherapy. Response was assessed by two central observers on pre- and post-chemotherapy enhanced scans using bi-dimensional criteria and as progression-free survival (PFS) at the time of second assessment prior to radiotherapy. Withdrawal from the study due to worsening clinical condition was, in the absence of second imaging, assessed as progressive disease. Survival and quality of life (QOL) were secondary endpoints. Results: Between August 1999 and June 2002, 188 patients from 15 UK and two Italian centres were entered into the study and 187 were analysed. Overall, 162 patients were assessable for response; seven had partial and 25 had minimal response. The objective response rate was 20{\%} [95{\%} confidence interval (CI) 14-26{\%}] and PFS prior to commencing radiotherapy was 64{\%} (95{\%} CI 57-72{\%}). The median survival was 10 months, and 1-year survival 41{\%}. The median survival of responders was 16 months compared to 3 months in patients with progressive disease (P",
keywords = "Malignant glioma, New agents, Temozolomide",
author = "Michael Brada and S. Ashley and A. Dowe and A. Gonsalves and A. Huchet and G. Pesce and M. Reni and F. Saran and B. Wharram and M. Wilkins and P. Wilkins",
year = "2005",
month = "6",
doi = "10.1093/annonc/mdi183",
language = "English",
volume = "16",
pages = "942--949",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "6",

}

TY - JOUR

T1 - Neoadjuvant phase II multicentre study of new agents in patients with malignant glioma after minimal surgery. Report of a cohort of 187 patients treated with temozolomide

AU - Brada, Michael

AU - Ashley, S.

AU - Dowe, A.

AU - Gonsalves, A.

AU - Huchet, A.

AU - Pesce, G.

AU - Reni, M.

AU - Saran, F.

AU - Wharram, B.

AU - Wilkins, M.

AU - Wilkins, P.

PY - 2005/6

Y1 - 2005/6

N2 - Background: The aim of this study was to assess the efficacy of new agents in patients with malignant glioma in a neoadjuvant setting not confounded by surgery. The first study of neoadjuvant temozolomide aimed to provide a benchmark for future evaluation of new treatments. Patients and methods: This was a multicentre phase II study of chemotherapy in patients with histologically verified glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA) who had undergone biopsy alone. Patients were planned to receive two cycles of temozolomide at 200 mg/m2 orally daily for 5 days at a 28-day interval prior to radiotherapy. Response was assessed by two central observers on pre- and post-chemotherapy enhanced scans using bi-dimensional criteria and as progression-free survival (PFS) at the time of second assessment prior to radiotherapy. Withdrawal from the study due to worsening clinical condition was, in the absence of second imaging, assessed as progressive disease. Survival and quality of life (QOL) were secondary endpoints. Results: Between August 1999 and June 2002, 188 patients from 15 UK and two Italian centres were entered into the study and 187 were analysed. Overall, 162 patients were assessable for response; seven had partial and 25 had minimal response. The objective response rate was 20% [95% confidence interval (CI) 14-26%] and PFS prior to commencing radiotherapy was 64% (95% CI 57-72%). The median survival was 10 months, and 1-year survival 41%. The median survival of responders was 16 months compared to 3 months in patients with progressive disease (P

AB - Background: The aim of this study was to assess the efficacy of new agents in patients with malignant glioma in a neoadjuvant setting not confounded by surgery. The first study of neoadjuvant temozolomide aimed to provide a benchmark for future evaluation of new treatments. Patients and methods: This was a multicentre phase II study of chemotherapy in patients with histologically verified glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA) who had undergone biopsy alone. Patients were planned to receive two cycles of temozolomide at 200 mg/m2 orally daily for 5 days at a 28-day interval prior to radiotherapy. Response was assessed by two central observers on pre- and post-chemotherapy enhanced scans using bi-dimensional criteria and as progression-free survival (PFS) at the time of second assessment prior to radiotherapy. Withdrawal from the study due to worsening clinical condition was, in the absence of second imaging, assessed as progressive disease. Survival and quality of life (QOL) were secondary endpoints. Results: Between August 1999 and June 2002, 188 patients from 15 UK and two Italian centres were entered into the study and 187 were analysed. Overall, 162 patients were assessable for response; seven had partial and 25 had minimal response. The objective response rate was 20% [95% confidence interval (CI) 14-26%] and PFS prior to commencing radiotherapy was 64% (95% CI 57-72%). The median survival was 10 months, and 1-year survival 41%. The median survival of responders was 16 months compared to 3 months in patients with progressive disease (P

KW - Malignant glioma

KW - New agents

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=21344454458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21344454458&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdi183

DO - 10.1093/annonc/mdi183

M3 - Article

VL - 16

SP - 942

EP - 949

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 6

ER -